Claims for Patent: 9,216,183

Summary for Patent: 9,216,183

Title:	Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract:	The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s):	Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/251,394
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,216,183
Patent Claims:	1. A method of growing eyelashes in chemotherapy patients, the method comprising applying 0.03% w/v bimatoprost at least once a day to the eyelids of a chemotherapy patient from at least one selected from the group consisting of before, during, and after chemotherapeutic treatment wherein patients receiving 0.03% w/v bimatoprost resulted in greater eyelash growth as compared to patients not receiving 0.03% w/v bimatoprost. 2. The method of claim 1, wherein 0.03% w/v bimatoprost is applied after chemotherapeutic treatment and results in greater eyelash growth in patients as compared to patients not receiving 0.03% w/v bimatoprost. 3. The method of claim 2, wherein the method results in eyelashes which are longer or thicker as compared to patients not receiving 0.03% w/v bimatoprost. 4. The method of claim 1, wherein the patients receiving 0.03% w/v bimatoprost before starting chemotherapeutic treatment resulted in greater eyelash growth as compared to patients receiving 0.03% w/v bimatoprost during or after chemotherapeutic treatment. 5. The method of claim 1, wherein 0.03% w/v bimatoprost is applied to the upper eyelid. 6. The method of claim 1, wherein 0.03% w/v bimatoprost is applied to the lower eyelid. 7. The method of claim 1, wherein the bimatoprost is added before, during and after chemotherapeutic treatment. 8. A method of treating eyelashes loss in chemotherapy patients, the method comprising applying 0.03% w/v bimatoprost at least once a day to the eyelids of a chemotherapy patient from at least one selected from the group consisting of before, during, and after chemotherapeutic treatment wherein patients receiving 0.03% w/v bimatoprost resulted in greater eyelash growth as compared to patients not receiving 0.03% w/v bimatoprost. 9. The method of claim 8, wherein 0.03% w/v bimatoprost is applied after chemotherapeutic treatment and results in greater eyelash growth in patients as compared to patients not receiving 0.03% w/v bimatoprost. 10. The method of claim 9, wherein the method results in eyelashes which are longer or thicker as compared to patients not receiving 0.03% w/v bimatoprost. 11. The method of claim 8, wherein the patients receiving 0.03% w/v bimatoprost before starting chemotherapeutic treatment resulted in greater eyelash growth as compared to patients receiving 0.03% w/v bimatoprost during or after chemotherapeutic treatment. 12. The method of claim 8, wherein 0.03% w/v bimatoprost is applied to the upper eyelid. 13. The method of claim 8, wherein 0.03% w/v bimatoprost is applied to the lower eyelid. 14. The method of claim 8, wherein the bimatoprost is applied after completing chemotherapeutic treatment. 15. The method of claim 14, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment. 16. The method of claim 12 wherein the method is applied prior to receiving chemotherapeutic treatment. 17. The method of claim 16, wherein the method is applied for six months after receiving chemotherapeutic treatment. 18. The method of claim 8 wherein the bimatoprost is in the form of a solution or an emulsion. 19. The method of claim 8 wherein the bimatoprost is applied to the upper eyelid or both the upper and lower eyelid. 20. The method of claim 8 wherein the method is applied after the patient completes chemotherapeutic treatment.